PTC Therapeutics (PTCT) Metrics: History & Chart

PTC Therapeutics, Inc.(PTCT)

Biotechnology · Warren, NJ

$63.77+0.12 (+0.19%)

Delayed quote: Oct 6, 2026, 1:55 PM EDT

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.

Warren, NJ

991 employees

www.ptcbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Matthew Klein

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-3.49%
30D Total Return	-8.15%
YTD Total Return	-16.21%
1Y Total Return	-2.63%
3Y Total Return	+186.70%
5Y Total Return	+74.26%
10Y Total Return	+364.40%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-16.21%
2025	+68.28%
2024	+63.79%
2023	-27.80%
2022	-4.17%
2021	-34.74%
2020

CAGR TTM	-2.62%
CAGR 3Y	+42.05%
CAGR 5Y	+11.75%
CAGR 10Y	+16.60%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	8.33
PE Ratio Avg TTM	8.39
PE Ratio Avg 3Y	8.39
Current VS TTM Avg	-0.70%
Current VS 3Y Avg	-0.70%
Current VS 5Y Avg	-0.70%

All Metrics

PTCT Valuation Metrics

PTCT Stock Price Metrics

PTCT Dividend Metrics

PTCT Growth Rate Metrics

PTCT Discounted Cash Flow Metrics

PTCT Returns By Period

PTCT Yearly Returns

PTCT Average Annual Returns By Period (CAGR)

PTCT Revenue Metrics

PTCT PE Ratio Metrics

PTCT PS Ratio Metrics

PTCT PB Ratio Metrics

PTCT Price to Free Cash Flow Ratio Metrics

PTCT Debt to Equity Ratio Metrics

PTCT PEG Ratio Metrics

PTCT FCF Yield

PTCT Earnings Yield

PTCT EBITDA Yield

PTCT OCF Yield

PTCT EV/EBIT Ratio Metrics

PTCT EV/EBITDA Ratio Metrics

PTCT EV/Assets Ratio Metrics

PTCT EV/Sales Ratio Metrics

PTCT Current Ratio Metrics

PTCT Quick Ratio Metrics

PTCT ROIC Metrics

PTCT Return on Assets Metrics

PTCT Return on Equity Metrics

PTCT Net Profit Margin Metrics

PTCT Gross Profit Margin Metrics

PTCT Tax Rate Metrics

PS Ratio	5.81
PS Ratio Avg TTM	4.89
PS Ratio Avg 3Y	3.12
Current VS TTM Avg	+18.85%
Current VS 3Y Avg	+86.42%
Current VS 5Y Avg	+41.92%

PB Ratio	1757.41
PB Ratio Avg TTM	17.66
PB Ratio Avg 3Y	7.11
Current VS TTM Avg	+9849.19%
Current VS 3Y Avg	+24613.46%
Current VS 5Y Avg	+27098.60%

PFCF Ratio	12.66
PFCF Ratio Avg TTM	10.35
PFCF Ratio Avg 3Y	10.35
Current VS TTM Avg	+22.36%
Current VS 3Y Avg	+22.36%
Current VS 5Y Avg	+22.36%

Debt/Equity Ratio	(4.21)
Debt/Equity Ratio Avg TTM	(4.82)
Debt/Equity Ratio Avg 3Y	(1.79)
Current VS TTM Avg	+12.61%
Current VS 3Y Avg	-135.05%
Current VS 5Y Avg	-113.49%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	7.90%
FCF Yield Avg TTM	11.26%
FCF Yield Avg 3Y	11.26%
Current VS TTM Avg	-29.85%
Current VS 3Y Avg	-29.85%
Current VS 5Y Avg	-29.85%

Earnings Yield	12.00%
Earnings Yield Avg TTM	12.01%
Earnings Yield Avg 3Y	12.01%
Current VS TTM Avg	-0.10%
Current VS 3Y Avg	-0.10%
Current VS 5Y Avg	-0.10%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	47.34
Ev/Ebit Ratio Avg TTM	8.26
Ev/Ebit Ratio Avg 3Y	6.61
Current VS TTM Avg	+473.30%
Current VS 3Y Avg	+616.60%
Current VS 5Y Avg	+616.60%

Ev/Ebitda Ratio	32.08
Ev/Ebitda Ratio Avg TTM	7.91
Ev/Ebitda Ratio Avg 3Y	107.60
Current VS TTM Avg	+305.42%
Current VS 3Y Avg	-70.19%
Current VS 5Y Avg	-70.19%

Ev/Assets Ratio	1.69
Ev/Assets Ratio Avg TTM	2.18
Ev/Assets Ratio Avg 3Y	1.84
Current VS TTM Avg	-22.33%
Current VS 3Y Avg	-8.20%
Current VS 5Y Avg	-12.75%

Ev/Sales Ratio	5.46
Ev/Sales Ratio Avg TTM	4.84
Ev/Sales Ratio Avg 3Y	3.34
Current VS TTM Avg	+12.70%
Current VS 3Y Avg	+63.46%
Current VS 5Y Avg	+20.08%

Current Ratio	3.39
Current Ratio Avg TTM	2.82
Current Ratio Avg 3Y	2.23
Current VS TTM Avg	+20.19%
Current VS 3Y Avg	+52.25%
Current VS 5Y Avg	+75.63%

Quick Ratio	3.28
Quick Ratio Avg TTM	2.74
Quick Ratio Avg 3Y	2.17
Current VS TTM Avg	+19.36%
Current VS 3Y Avg	+50.98%
Current VS 5Y Avg	+74.56%

ROIC	4.59%
ROIC Avg 3Y	(9.56%)
ROIC Avg 5Y	(15.64%)
Current VS 3Y Avg	+147.98%
Current VS 5Y Avg	+129.33%
Current VS 10Y Avg	+122.21%

ROA	(1.18%)
ROA Avg TTM	(0.81%)
ROA Avg 3Y	(3.89%)
Current VS TTM Avg	-45.83%
Current VS 3Y Avg	+69.65%
Current VS 5Y Avg	+78.36%

ROE	N/A
ROE Avg TTM	(193.02%)
ROE Avg 3Y	(61.34%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(3.80%)
Net Profit Margin Avg TTM	(17.71%)
Net Profit Margin Avg 3Y	(31.39%)
Current VS TTM Avg	+78.54%
Current VS 3Y Avg	+87.89%
Current VS 5Y Avg	+93.44%

Gross Profit Margin	95.85%
Gross Pft Margin Avg TTM	82.59%
Gross Pft Margin Avg 3Y	93.41%
Current VS TTM Avg	+16.05%
Current VS 3Y Avg	+2.61%
Current VS 5Y Avg	+2.70%

Tax Rate	14.40%
Tax Rate Avg 3Y	10.60%
Tax Rate Avg 5Y	10.60%
Current VS 3Y Avg	+35.83%
Current VS 5Y Avg	+35.83%
Current VS 10Y Avg	-28.82%